Tessa Romero
Stock Analyst at JP Morgan
(4.40)
# 325
Out of 5,140 analysts
77
Total ratings
52.54%
Success rate
22.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tessa Romero
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DYN Dyne Therapeutics | Maintains: Neutral | $17 → $16 | $17.97 | -10.94% | 8 | Jan 20, 2026 | |
| CYTK Cytokinetics | Maintains: Overweight | $70 → $74 | $64.83 | +14.14% | 6 | Jan 20, 2026 | |
| XENE Xenon Pharmaceuticals | Maintains: Overweight | $60 → $62 | $42.40 | +46.23% | 4 | Jan 9, 2026 | |
| AGIO Agios Pharmaceuticals | Maintains: Neutral | $20 → $25 | $28.46 | -12.16% | 8 | Jan 6, 2026 | |
| OCS Oculis Holding AG | Initiates: Overweight | $38 | $26.83 | +41.62% | 1 | Dec 19, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $47 → $15 | $13.61 | +10.21% | 8 | Nov 20, 2025 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $46 → $47 | $46.91 | +0.19% | 6 | Nov 18, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Underweight | $261 → $263 | $3.83 | +6,766.84% | 1 | Nov 18, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Overweight | $33 → $31 | $27.47 | +12.87% | 11 | Nov 17, 2025 | |
| EWTX Edgewise Therapeutics | Maintains: Overweight | $33 → $34 | $29.72 | +14.40% | 11 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.02 | - | 5 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $10 | $7.78 | +28.53% | 2 | May 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $31.88 | +19.20% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $15.65 | - | 2 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $29 | $16.20 | +79.07% | 3 | Aug 13, 2024 |
Dyne Therapeutics
Jan 20, 2026
Maintains: Neutral
Price Target: $17 → $16
Current: $17.97
Upside: -10.94%
Cytokinetics
Jan 20, 2026
Maintains: Overweight
Price Target: $70 → $74
Current: $64.83
Upside: +14.14%
Xenon Pharmaceuticals
Jan 9, 2026
Maintains: Overweight
Price Target: $60 → $62
Current: $42.40
Upside: +46.23%
Agios Pharmaceuticals
Jan 6, 2026
Maintains: Neutral
Price Target: $20 → $25
Current: $28.46
Upside: -12.16%
Oculis Holding AG
Dec 19, 2025
Initiates: Overweight
Price Target: $38
Current: $26.83
Upside: +41.62%
Biohaven
Nov 20, 2025
Maintains: Overweight
Price Target: $47 → $15
Current: $13.61
Upside: +10.21%
Scholar Rock Holding
Nov 18, 2025
Maintains: Overweight
Price Target: $46 → $47
Current: $46.91
Upside: +0.19%
Rocket Pharmaceuticals
Nov 18, 2025
Downgrades: Underweight
Price Target: $261 → $263
Current: $3.83
Upside: +6,766.84%
ACADIA Pharmaceuticals
Nov 17, 2025
Maintains: Overweight
Price Target: $33 → $31
Current: $27.47
Upside: +12.87%
Edgewise Therapeutics
Nov 14, 2025
Maintains: Overweight
Price Target: $33 → $34
Current: $29.72
Upside: +14.40%
Sep 16, 2025
Downgrades: Underweight
Price Target: n/a
Current: $2.02
Upside: -
May 30, 2025
Maintains: Overweight
Price Target: $16 → $10
Current: $7.78
Upside: +28.53%
Nov 5, 2024
Initiates: Overweight
Price Target: $38
Current: $31.88
Upside: +19.20%
Oct 24, 2024
Downgrades: Underweight
Price Target: n/a
Current: $15.65
Upside: -
Aug 13, 2024
Maintains: Overweight
Price Target: $32 → $29
Current: $16.20
Upside: +79.07%